A Patient-Centered Approach to CDK4/6 Inhibitors

1 rich Libsyn https://www.libsyn.com 90 600 A Patient-Centered Approach to CDK4/6 Inhibitors The George Washington Cancer Center serves a racially, ethnically, and socioeconomically diverse population across Washington, D.C., northern Virginia, and southern Maryland. Their Breast Cancer Program has found that a community-informed model is most successful for managing care and adverse events related to CDK4/6 inhibitors. In this episode, CANCER BUZZ speaks with Pavani Chalasani, MD, MPH, director of the division of hematology/oncology at the George Washington University Cancer Center about the flexible and collaborative team design that allows for culturally responsive and comprehensive care for their patients with breast cancer. &nbsp; Pavani Chalasani, MD, MPH&nbsp; Director, Division of Hematology/Oncology George Washington University Cancer Center Washington, DC &nbsp; “I think adapting and knowing what the barriers are and how we can divide and support and come up with roles for our team members is essential.” “[Navigators] give us an understanding of where the hesitancy is coming from, or where the concerns are coming from, so that we can do a better job explaining and overcoming those barriers.” &nbsp; Resources ·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spotlight on George Washington (GW) Cancer Center: Managing Adverse Effects of CDK4/6 Inhibitors With a Patient-Centered, Team-Based Approach ·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACCC Resource: CDK4/6 Inhibitors Management ·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACCC CDK4/6 Inhibitors Infographic CANCER BUZZ https://www.accc-cancer.org <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/38500580/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/item/38500580